Position in RPRX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$900,428
+$520,362 QoQ
Shares Held
16,059
+102.7% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#341
of 641 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 68%
Shared 16%
None 15%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Savant Capital, LLC holds $23,538,035 across 24 Biotechnology names. RPRX ranks #5 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,241 | $13,034,691 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,687 | $2,298,991 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
4,776 | $1,150,872 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
12,479 | $929,435 | |
| 5 | RPRX |
Royalty Pharma plc
This page
|
16,059 | $900,428 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
6,935 | $602,998 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
7,476 | $592,772 | |
| 8 | MRNA |
Moderna, Inc.
|
7,432 | $520,462 |
All Filings in RPRX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $900,428 | 16,059 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $380,066 | 7,923 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $280,719 | 7,265 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $261,601 | 7,415 | Shares | Sole | 2026-03-04 | |
| 2025-06-30 | $254,119 | 7,053 | Shares | Sole | 2026-03-04 | |
| No filing history on record for this holder in this stock. | ||||||